Scott Patterson, PhD, is Vice President, Biomarker Sciences in the R&D organization at Gilead Sciences, Inc, where he is responsible for development and implementation of biomarker and diagnostic strategies across all the company’s therapeutic areas. Previously, he was Executive Director, Medical Sciences at Amgen, Inc, where he established the company’s biomarker strategy and led the In Vitro Diagnostics Group from its inception. Prior to Amgen, Dr. Patterson was Vice President, Proteomics at Celera Genomics. Earlier in his career, he held research appointments at Amgen and at Cold Spring Harbor Laboratory, New York. Dr. Patterson received BSc and PhD degrees from The University of Queensland in Australia.
Integrating real-world evidence in all phases of development allows moving from discovery into viable companion diagnostics. However, it doesn’t stop with access; the quality and quantity of RWE data contributes far more complexity. This panel will discuss the promise and challenges in the accelerated time to market for fit-for-patient diagnostics using RWE data.